Search
Pennsylvania Paid Clinical Trials
A listing of 3293 clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
949 - 960 of 3293
Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Allentown, Pennsylvania
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Recruiting
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Allergy and Clinical Immunology Associates, Pittsburgh, Pennsylvania
Conditions: Chronic Spontaneous Urticaria (CSU)
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Recruiting
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Altoona Center For Clinical Research, Duncansville, Pennsylvania
Conditions: Obesity
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: UP Medical Center H System, Pittsburgh, Pennsylvania
Conditions: Hidradenitis Suppurativa
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/28/2025
Locations: Frontier Clinical Re search, LLC, Uniontown, Pennsylvania
Conditions: Moderately to Severely Active Ulcerative Colitis
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Recruiting
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Metastatic Castration-resistant Prostate Cancer
A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair
Recruiting
This is a multicenter, prospective, randomized, subject and evaluator blinded clinical trial to asses the efficacy of Auxilium's NeuroSpan Bridge.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2025
Locations: University of Pennsylvania- Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Peripheral Nerve Injuries
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2025
Locations: Akero Clinical Study Site, Philadelphia, Pennsylvania
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Recruiting
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Gender:
ALL
Ages:
Between 3 years and 75 years
Trial Updated:
07/28/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Severe Aplastic Anemia
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Recruiting
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Site 151, Bensalem, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Recruiting
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Penn State Health Hershey Medical Center, Hershey, Pennsylvania
Conditions: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
ADVENT Post Approval Study
Recruiting
The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Pinnacle Health at Harrisburg Hospital, Harrisburg, Pennsylvania
Conditions: Paroxysmal Atrial Fibrillation